Food and Drug Administration
Center for Biologics Evaluation and Research
Summary Minutes
191st Vaccines and Related Biological Products Advisory Committee Meeting
March 12, 2026

Committee Members
Archana Chatterjee, MD, PhD+
Anna Durbin, MD
Hayley Gans, MD
CAPT Sarah Meyer, MD, MPH
Flor M. Munoz-Rivas, MD MSc+
Michael R. Nelson, MD, PhD+
Saad B. Omer, MBBS, MPH, PhD+

Industry Representative Member
Temi Folaranmi, MD, MPH, MPP***+

Alternate Industry Representative Member
James Kollar, MD ~

Temporary Voting Members
Adam Berger, PhD
Hana M. El Sahly, MD
Arnold S. Monto, MD (*Acting)
Stanley M. Perlman, MD, PhD
Eric J. Rubin, MD, PhD

Temporary Non-voting Member
Jay M. Portnoy, MD (**Acting)

Speakers and Guest Speakers
CDC Speaker:
Rebecca J. Garten Kondor, PhD
CDC Speaker:
Lisa Grohskopf, MD, MPH

DoD Speaker:
William Gruner, MS, MB (ASCP), CM

Industry Speaker

Beverly Taylor, PhD

FDA Participants
David C. Kaslow, MD
Jerry Weir, PhD
Zhiping Ye, PhD
Sudhakar Agnihothram, BPharm, PhD
Manju Joshi, PhD (Presenter)

Designated Federal Officer (DFO)
LCDR Cicely Reese, PharmD

+Not Attending
*Chairperson
**Consumer Representative
***Industry Representative
~Alternate Industry Representative

These summary minutes for the March 12, 2026, meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) were approved on the XX of May 2026.

I certify that I participated in the March 12, 2026, meeting of the VRBPAC meeting and that these minutes accurately reflect what transpired.

/s/
Cicely Reese, PharmD, LCDR
USPHS, DFO

/s/
Arnold S. Monto, MD
Acting Chairperson

Food and Drug Administration
Center for Biologics Evaluation and Research
Summary Minutes
191st Vaccines and Related Biological Products Advisory Committee Meeting
March 12, 2026

On March 12, 2026, the 191st meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season. Given the topic, the meeting was determined to be a Particular Matter Involving Specific Parties (PMISP).

On March 12, 2026, at 9:00 a.m. Eastern Daylight Time (EDT), Dr. Arnold Monto, Chairperson, called the meeting to order. The DFO, Dr. Cicely Reese, made administrative remarks, conducted rollcall, invited the VRBPAC members and consultants to introduce themselves, and read the Conflict of Interest (COI) statement into the public record. There were no conflict-of-interest waivers issued under 18 U.S. Code Section 208 in connection with this meeting.

Dr. Arnold Monto, Chairperson, convened the Open Public Hearing (OPH). Three registered speakers presented remarks during the OPH. The Chairperson closed the session and moved into presentations to the Committee.

During the open session, the VRBPAC members, consultants, FDA speakers and staff, and invited Guest speakers participated via Zoom web conference.

Dr. Jerry Weir, Director, Division of Viral Products, Office of Vaccines Research and Review, provided the Introduction to the VRBPAC Meeting Topics, followed by a brief Questions and Answers (Q&A).

Following Introductory Remarks, Center for Disease Control and Prevention (CDC), Department of War (DoW), and FDA speakers, as well as an influenza vaccine manufacturing representative speaker provided presentations entitled:

- CDC: U.S. Influenza Surveillance and Preliminary Vaccine Effectiveness Estimates, 2025-26 Season: Lisa Grohskopf, MD, MPH
- CDC: Global Influenza Virus Surveillance and Characterization: Rebecca Kondor, PhD
- DoD: Department of War Influenza Surveillance and Mid-Season Vaccine Effectiveness: Bill Gruner, MS, MB (ASCP)
- FDA: Candidate Vaccine Strains and Potency Reagents: 2026-27 Northern Hemisphere Influenza Season: Manju Joshi, PhD
- Influenza Vaccine Manufacturing Representative: 2025-2026 and upcoming 2026-2027 Northern Hemisphere Influenza Seasons: Beverly Taylor, PhD, CSL Seqirus

A brief 10-minute break was held after the first CDC presentation, and a 30-minute lunch break was held after the second CDC presentation. Each of the presentations was followed by Q&A sessions with the Committee.

Immediately following the last Q&A session, the Chairperson began the Committee Discussion of the topic, and the voting questions were presented to the Committee.

After Committee Discussion concluded, the Chairperson and DFO invited and led the Committee into the voting session. The outcome of the voting questions is noted below *(Dr. Eric Rubin was not present after 2:00 pm EDT; not present for vote)*:

Voting Question 1: Does the committee recommend a 2026-2027 formulation for egg-based influenza virus vaccines in the U.S. that contain the following virus strains:
•An A/Missouri/11/2025 (H1N1)pdm09-like virus;
•An A/Darwin/1454/2025 (H3N2)-like virus; and
•A B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus

The vote was Yes: 7 No: 0 Abstain: 0.

Voting Question 2: Does the committee recommend a 2026-2027 formulation for cell- and recombinant-based influenza vaccines in the U.S. that contain the following virus strains:
•An A/Missouri/11/2025 (H1N1)pdm09-like virus;
•An A/Darwin/1415/2025 (H3N2)-like virus; and
•A B/Pennsylvania/14/2025 (B/Victoria lineage)

The vote was Yes: 7 No: 0 Abstain: 0.

Meeting Summary:
There was a general agreement among the committee members that the data presented was informative and convincing about the need to change influenza A/H1N1, A/H3N2 and B virus strains contained in the 2026-2027 formulation. Committee members also discussed the potential for including two influenza A/H3N2 strains in future influenza vaccines to address the ongoing challenges with antigenic drift in the influenza A/H3 subtype and acknowledged the regulatory challenges associated with licensing these potential quadrivalent formulations. Committee members emphasized the need for influenza vaccines with broader coverage and importance of global surveillance and partnership in influenza vaccine strain selection.

Following Committee voting and the summary, Acting Chairperson, Dr. Arnold Monto, invited Dr. David C. Kaslow to provide closing remarks. Dr. Kaslow thanked the committee for the 191st VRBPAC meeting, which discussed the 2026-2027 influenza vaccine formula using comprehensive domestic and global surveillance data. He acknowledged that the discussion went beyond the voting questions to address emerging issues and scientific challenges in tracking rapidly evolving influenza viruses. Dr. Kaslow expressed gratitude to the public hearing speakers, invited presenters, FDA staff, and VRBPAC members for their contributions to the evidence-driven discussion. He emphasized that the committee's service is vital for enhancing public trust and looked forward to the 192nd VRBPAC meeting.

Following Dr. Kaslow's closing remarks, the committee DFO adjourned the meeting on March 12, 2026, at 2:39 p.m. EDT.

Additional meeting information and details may be obtained from the transcript, which may be viewed at:
2026 Meeting Materials, Vaccines and Related Biological Products Advisory Committee | FDA

The recording of the webcast of the meeting may be viewed at:
https://youtube.com/live/WKw0WEik5y4?feature=share